Monitoring of Arrhythmias and HRV in Patients With Heart Failure Treated With the CRT Pacemaker Renewal TR2
Congestive Heart Failure
About this trial
This is an interventional diagnostic trial for Congestive Heart Failure
Eligibility Criteria
Inclusion Criteria: Moderate or severe chronic heart failure, defined by the presence of NYHA class III or IV symptoms, Intra/interventricular synchronization disorder evaluated by echocardiography and/or Doppler Tissue Imaging (DTI, Yu's method22), Ejection fraction (EF) ≤ 40 %, If previous history of myocardial infarction, MI must be > 60 days from the date of inclusion, Estimated life expectancy > 6 months in the case of concomitant disease, Age ≥ 18 years, Optimal drug treatment of chronic heart failure (according to SFC* recommendations). Exclusion Criteria: Conventional indication for treatment by implantable defibrillator upon inclusion, Cardiac transplant envisaged within 6 months, Unexplained syncope, MI < 60 days before inclusion, Non compliance to drug treatment for chronic heart failure, Any coronary pathology which may be treated by revascularisation.
Sites / Locations
- CHG Albi
- CHU Michalon
- CH La Croix Rousse
- Hôpital Louis Pradel
- Nouvelle Clinique Nantaise
- CHU Nîmes
- CHG Perigueux
- Hôpital Pontchaillou
- Centre Cardiologique du Nord
- Clinique Pasteur